Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateBusiness Wire • 05/13/25
RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025Business Wire • 05/12/25
Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025Business Wire • 05/01/25
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor SymposiumBusiness Wire • 04/22/25
Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)Business Wire • 04/21/25
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateBusiness Wire • 03/10/25
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025Business Wire • 03/05/25
Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences ConferenceBusiness Wire • 02/04/25
Lineage Cell (LCTX) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 01/30/25
Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct OfferingBusiness Wire • 01/27/25
Down -43.14% in 4 Weeks, Here's Why Lineage Cell (LCTX) Looks Ripe for a TurnaroundZacks Investment Research • 12/17/24
Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct OfferingBusiness Wire • 11/21/24
Lineage Cell (LCTX) Loses -26.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 11/21/24
Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct OfferingBusiness Wire • 11/20/24
Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire • 11/14/24
Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024Business Wire • 11/07/24
Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare SummitBusiness Wire • 10/14/24
OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International SymposiumBusiness Wire • 09/25/24
Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology WorkshopBusiness Wire • 09/18/24